Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.

ABSTRACT:

Background

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, some patients do not respond well, and some experience rapid progression despite initial benefit. This study aims to develop multimodal models integrating pre-treatment histopathological images and clinical variables to predict EGFR-TKIs therapy response and progression-free survival (PFS) in stage IV NSCLC patients.

Methods

This retrospective study collected hematoxylin and eosin (H&E)-stained whole-slide images (WSIs) and clinical variables, including clinical characteristics and laboratory indicators, from 247 treatment-naïve, stage IV EGFR-mutated NSCLC pat

SUBMITTER: Chai X 

PROVIDER: S-EPMC12362994 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature